Genetic Effects on Rifampin Drug Response
Rifampin (also known as Rifampicin) is a key antibacterial drug used in the treatment of Tuberculosis (TB) and other bacterial infections. It works by inhibiting bacterial RNA polymerase, blocking the synthesis of RNA and ultimately killing the bacteria.
How Rifampin Works
Rifampin binds to the beta subunit of bacterial DNA-dependent RNA polymerase, preventing transcription of DNA into mRNA. This mechanism is highly specific to bacterial RNA polymerase and does not significantly affect human RNA polymerase — making it an effective and targeted antibiotic.
The Role of NAT2 Genetics
Individuals who carry NAT2 (N-acetyltransferase 2) gene variants may need modified dosing or alternate therapy. NAT2 is responsible for the acetylation (metabolism) of several drugs including isoniazid, which is commonly used alongside rifampin in TB treatment. NAT2 variants determine whether a patient is a:
Slow acetylator: Drug accumulates in the body, increasing the risk of toxicity (especially liver toxicity/hepatotoxicity)
Rapid acetylator: Drug is metabolised too quickly, potentially reducing therapeutic efficacy
In India, where TB remains a significant public health challenge, understanding a patient’s NAT2 status before initiating TB therapy can help personalise dosing, reduce adverse drug reactions, and improve treatment outcomes.
Other Relevant Pharmacogenes
CYP2C9 and CYP3A4: Influence rifampin’s own metabolism and its interactions with other co-administered drugs
SLCO1B1: Affects hepatic uptake of rifampin and influences drug exposure levels
Know How Your Genes Affect Your Medications
MedicaMap by MapmyGenome analyses your NAT2, CYP2C9, CYP3A4, and 100+ other pharmacogenomic markers — helping your doctor select the right antibiotic at the right dose and avoid preventable adverse reactions including drug-induced liver injury.
